Accueil » La R&D d'Unicancer » Les publications de la R&D d'Unicancer » Communications orales et posters

Communications et posters de la R&D d'Unicancer

2016

Genomic analysis to evaluate response to neoadjuvant anastrozole and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCBG CARMINA02 trial

Céline Callens et al., SABCS

2016

Ewing sarcoma of the head and neck: local treatment evaluation of the French population of Euro-Ewing99

J. Bouaoud et al., EMSOS 2016

2016

High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: first feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG- 0105/1304)

A.Gonçalves et al., SABCS 2016

2016

Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).

Bernard M. Dubray et al., ASCO 2016

2016

Efficacy and tolerance of treatments received beyond progression in men with metastatic hormone-naive prostate cancer treated with androgen deprivation therapy (ADT) with or without docetaxel in the GETUG-AFU 15 phase III trial.

Pernelle Lavaud et al., ASCO 2016

2016

Détermination du spectre tumoral, de la pénétrance et de l'utilité clinique des mutations constitutionnellesdans les nouveaux gènes de prédisposition aux cancers du sein et de l'ovaire : l'étude TUMOSPEC

O. Caron et al., 8e assises de génétique humaine et médicale

2016

Crizotinib in children and adolescents with advanced ROS1, MET or ALK-rearranged cancer: results of the AcSé phase II trial

G. Vassal et al., ASCO 2016

2016

Efficacy of Busulfan-Melphalan high dose chemotherapy consolidation in localised high-risk Ewing sarcoma: Results of EURO-E.W.I.N.G 99 R2Loc randomised trial.

Jeremy Whelan et al., ASCO 2016

2016

Comparison of VAI standard chemotherapy & whole lung irradiation and Busulfan-Melphalan high dose chemotherapy in Ewing sarcoma (EwS) patients with pulmonary metastases: Results of EURO-E.W.I.N.G. 99 R2pulm randomised trial.

Uta Dirksen et al., ASCO 2016

2016

Disease free survival (DFS) is a surrogate for Overall Survival (OS) in Localized Prostate Cancer (CaP).

Christopher Sweeney et al., ASCO 2016